Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Peter Chen, Ajay Nirula, Barry N. Heller, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 3, pp. 229-237
Open Access | Times Cited: 1347

Showing 1-25 of 1347 citing articles:

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Pengfei Wang, Manoj S. Nair, Lihong Liu, et al.
Nature (2021) Vol. 593, Iss. 7857, pp. 130-135
Open Access | Times Cited: 2239
Adaptive immunity to SARS-CoV-2 and COVID-19
Alessandro Sette, Shane Crotty
Cell (2021) Vol. 184, Iss. 4, pp. 861-880
Open Access | Times Cited: 1749
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
David M. Weinreich, Sumathi Sivapalasingam, Thomas Norton, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 3, pp. 238-251
Open Access | Times Cited: 1693
Severe Covid-19
David Berlin, Roy M. Gulick, Fernando J. Martínez
New England Journal of Medicine (2020) Vol. 383, Iss. 25, pp. 2451-2460
Closed Access | Times Cited: 1390
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Constantinos Kurt Wibmer, Frances Ayres, Tandile Hermanus, et al.
Nature Medicine (2021) Vol. 27, Iss. 4, pp. 622-625
Open Access | Times Cited: 1233
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Elisabetta Cameroni, John E. Bowen, Laura E. Rosen, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 664-670
Open Access | Times Cited: 1106
Viral targets for vaccines against COVID-19
Lianpan Dai, George F. Gao
Nature reviews. Immunology (2020) Vol. 21, Iss. 2, pp. 73-82
Open Access | Times Cited: 1055
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Markus Hoffmann, Prerna Arora, Rüdiger Groß, et al.
Cell (2021) Vol. 184, Iss. 9, pp. 2384-2393.e12
Open Access | Times Cited: 991
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
Robert Gottlieb, Ajay Nirula, Peter Chen, et al.
JAMA (2021) Vol. 325, Iss. 7, pp. 632-632
Open Access | Times Cited: 884
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
Romina Libster, Gonzalo Pérez Marc, Diego Wappner, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 7, pp. 610-618
Open Access | Times Cited: 858
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Zhuoming Liu, Laura A. VanBlargan, Louis-Marie Bloyet, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 3, pp. 477-488.e4
Open Access | Times Cited: 809
COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection
Stephany Beyerstedt, Expedito Barbosa Casaro, Érika Bevilaqua Rangel
European Journal of Clinical Microbiology & Infectious Diseases (2021) Vol. 40, Iss. 5, pp. 905-919
Open Access | Times Cited: 721
Neutralizing monoclonal antibodies for treatment of COVID-19
Peter C. Taylor, Andrew C. Adams, Matthew M. Hufford, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 6, pp. 382-393
Open Access | Times Cited: 706
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
Anil Kumar Gupta, Yaneicy Gonzalez‐Rojas, Erick Stanley Petersen Juárez, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 21, pp. 1941-1950
Open Access | Times Cited: 630
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
Emma C. Thomson, Laura E. Rosen, James G. Shepherd, et al.
Cell (2021) Vol. 184, Iss. 5, pp. 1171-1187.e20
Open Access | Times Cited: 623
Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
Pengfei Wang, Ryan G. Casner, Manoj S. Nair, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 5, pp. 747-751.e4
Open Access | Times Cited: 613
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
Paul Bastard, Adrian Gervais, Tom Le Voyer, et al.
Science Immunology (2021) Vol. 6, Iss. 62
Open Access | Times Cited: 496
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
Tyler N. Starr, Allison J. Greaney, Adam S. Dingens, et al.
Cell Reports Medicine (2021) Vol. 2, Iss. 4, pp. 100255-100255
Open Access | Times Cited: 493
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
Jens Lundgren, Birgit Grund, Christina E. Barkauskas, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 10, pp. 905-914
Open Access | Times Cited: 427
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
Bryan E. Jones, Patricia Brown‐Augsburger, Kizzmekia S. Corbett, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 593
Open Access | Times Cited: 426
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
Michael Dougan, Ajay Nirula, Masoud Azizad, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 15, pp. 1382-1392
Open Access | Times Cited: 405
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Kathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Cell Reports (2022) Vol. 39, Iss. 7, pp. 110812-110812
Open Access | Times Cited: 396
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
Naveenchandra Suryadevara, Swathi Shrihari, Pavlo Gilchuk, et al.
Cell (2021) Vol. 184, Iss. 9, pp. 2316-2331.e15
Open Access | Times Cited: 382
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
Gilmar Reis, Eduardo Augusto dos Santos Moreira-Silva, Daniela Carla Medeiros Silva, et al.
The Lancet Global Health (2021) Vol. 10, Iss. 1, pp. e42-e51
Open Access | Times Cited: 373
Tackling COVID-19 with neutralizing monoclonal antibodies
Davide Corti, Lisa A. Purcell, Gyorgy Snell, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3086-3108
Open Access | Times Cited: 369
Page 1 - Next Page

Scroll to top